The Guardian recently released an article featuring ITCMS Director, Channing Der, PhD, as an experienced guide through the history of the “Undruggable RAS Mutation.”
Channing has been involved in this discovery since the early 1980s. When he was a young scientist at Harvard, he discovered the unique RAS mutation. This oncogene controls the “On/Off” switch of tumor growth and is notorious for its lack of nooks and crannies, which scientists typically exploit to attach cancer drugs.
KRAS, in particular, is a focus of the Der lab, which is found in most pancreatic cancers.
You can read the full article here, to learn more about Channing’s involvement with this mutation and its impact in the field of cancer biology.